Synergism between vasopressin and phorbol esters in stimulation of insulin secretion and phosphatidylcholine metabolism in RIN insulinoma cells

Biochem Biophys Res Commun. 1988 Mar 15;151(2):717-24. doi: 10.1016/s0006-291x(88)80339-5.

Abstract

The tumor promoter, tetradecanoylphorbolacetate (TPA), causes a significant increase in both insulin secretion and the incorporation of 32Pi into phosphatidylcholine (PC) in RIN insulinoma cells. The peptide hormone, arginine vasopressin (AVP), also stimulates these functions, although to a lesser degree. When added together, the effects on secretion and PC metabolism are synergistic. At the same time, TPA inhibits the AVP-stimulated rise in phosphoinositide (PI) metabolism. Neither phloretin nor tamoxifen, reported to be inhibitors of protein kinase C activity, are able to block the effects of TPA on secretion, although both influence PC metabolism.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenoma, Islet Cell / metabolism*
  • Animals
  • Arginine Vasopressin / pharmacology*
  • Cell Line
  • Drug Synergism
  • Insulinoma / metabolism*
  • Kinetics
  • Pancreatic Neoplasms / metabolism*
  • Phloretin / pharmacology
  • Phosphatidylcholines / metabolism*
  • Rats
  • Tamoxifen / pharmacology
  • Tetradecanoylphorbol Acetate / pharmacology*

Substances

  • Phosphatidylcholines
  • Tamoxifen
  • Arginine Vasopressin
  • Tetradecanoylphorbol Acetate
  • Phloretin